. Author manuscript; available in PMC: 2016 Jan 31.

Published in final edited form as: Bone Marrow Transplant. 2015 Apr 27;50(8):1057–1062. doi: 10.1038/bmt.2015.82

Table 4.

Multivariate analysis of outcome

		Univariate		Multivariate^‡
Outcome	N	RR (95% CI)	P	RR (95% CI)	P
Overall Survival
no-EMD	8983	1.00	0.73	1.00	0.91
EMD	814	1.02 (9.03–1.11)		1.00 (0.91–1.09)
Leukemia Free Survival
no-EMD	8877	1.00	0.58	1.00	0.74
EMD	804	1.03 (0.94–1.12)		0.98 (0.89–1.09)
Treatment Related Mortality
no-EMD	8877	1.00	0.05	1.00	0.23
EMD	804	0.87 (0.76–1.00)		0.92 (0.80–1.06)
Relapse
no-EMD	8877	1.00	0.01	1.00	0.62
EMD	804	1.16 (1.03–1.30)		1.03 (0.92–1.16)

^‡

MVA model adjusted for: WBC at diagnosis, previous history of MDS, cytogenetic risk group, disease status prior to HSCT, duration of CR1, site of relapse for patients transplanted in >=CR2, time from diagnosis to HSCT, consolidation treatment, age group, conditioning regimen, type of donor, graft type, CMV serostatus, year of HSCT, GVHD prophylaxis.

DLI was excluded from model.